The performance characteristics of an immunoradiometric assay for bone alkaline phosphatase mass concentration in human sera are reported.
Introduction
Several methods have been recommended for differentiating between liver and bone alkaline phosphatases, Human alkaline phosphatases (orthophosphoric mono-based on the fo i lowing p ri nc iples: ester phosphohydrolase [alkaline Optimum], EC 3.1.3.1) are glycoproteins which can bedivided into at least four ( a ) Separation of bone and liver isoforms by electroisoenzyme groups: intestinal, placental, placental-like pnoresis (2) and hepatic/renal/skeletal. The alkaline phosphatases of (b) Precipitation of bone alkaline phosphatase with bone and liver are coded by a sragle gene but differ in wheat-germ lectin, which leaves non-bone alkaline their degree of glycosylation (for review see 1. c. (1)).
phosphatases in the supernate (3).
Here we report on the evaluation of an immunoradiometric method for determination of bone alkaline phosphatase mass concentration in human sera. The method employs two monoclonal antibodies, which react with different epitopes of the bone alkaline phosphatase molecule.
Materials and Methods
Reference individuals and patients Sera were obtained frorn (a) 102 apparently healthy persons (51 males and 51 females, respectively), age r nge 20-55 years (median: 30 years) for males, and 18-56 years (median: 29 years) for females.
(b) 32 patients receiving renal transplants (10 sera before and 79 sera l week to 6 months after transplantation).
(c) 20 patients with various hepatobiliary diseases.
All specimens were taken between 8 and 9 a. m. Sera were separated frorn the blood clot within 4 h after specimen collection and stored at -20 °C for a period of up to 2 months. : 100 μΐ of serum were mixed with 100 μΐ of a solution containing wheat-germ lectin (> 2 g/l) for precipitatioh of bone alkaline phosphatase and Triton X-100 (20 g/l) to prevent coprecipitation of biliary alkaline phosphatase. After incubation for 30 min at room temperature the mixture was centrifuged at 2500 g for 10 min. The activity of total alkaline phosphatase in serum and of alkaline phosphatase in the supernate was measured at + 25 °C by the optimized Standard method according to the Recommendations of the German Society for Clinical Chemistry (4) using the fully mechanized analyser Hitachi/BM 704 (Boehririger Mannheim GmbH, Mannheim, Gerraany). Bone alkaline phosphatase activity concentration was caiculated with the aid of the following equation which takes into account dilution of serum by the precipitating reagent s well s an average of 10% residual activity of bone alkaline phosphatase in the supernate and an average of 5% of nonbone alkaline phosphatase in the precipitate (5) 
Statistical analysis
The statistical methods employed include the U-test according to Wilcoxon, Mann & Whitney (two-tailed), linear correlatipn coefficients and linear regression equations (7).
Results

Imprecision
Two pooled human sera were analysed 20 times for determination of bone alkaline phosphatase mass concentration and activity concentration, respeetively, in order to assess within-run imprecision (tab. 1). The results of between-day imprecision are shown in table 2.
Assay limit of detection
Twenty replicate analyses of the zero Standard were made within a single run, and the assay limit of detection, defined s the concentration cprresponding to the 95% confidence interval of counts, was found to be 0.3
Linearity and dilution
Linearity of dilution was investigated using 2 human serum samples containing 22.6 and 81.4 μg/l bone alka* Tab. l Comparison of the immunoradiometric determination of bone alkaline phosphatase mass concentration and the determination of bone alkaline phosphatase activity concentration by precipitation with wheatrgerm lectin, with respect to within-run imprecision (n = 20 figure 1 . The corresponding regression line did not significantly differ from the bisector of the diagram. After correcting the measured concentrations for the dilution factor and expressing them s a percentage of the concentration measured in the undiluted sample, the recovery was found to r nge from 88% to 113% (mean: 103%). regression equations obtained (see legends to figs. 2 and 3) it can be calculated that a bone alkaline phosphatase activity concentration of 100 U/l corresponds to a bone alkaline phosphatase mass concentration of 26 μg/l.
Reference interval
In apparently healthy persons bone alkaline phosphatase mass concentration was higher in males than in females (p < 0.0001). The reference intervals (2.5th-97.5th percentile) are 3.8-21.3 μg/l (median: 10.2 μg/l) (males) and 3.4-15.0 μg/l (median: 6.9 μg/l) (females) (fig.4 ). Interference by non-bone alkaline phosphatase
In 20 sera ftom patients with hqpatobiliary diseases the ränge of total alkaline phosphatase activity concentration was 217-3270 U/l (median: 376 U/l), and of L--glutamyl transferase activity .concentration 25-640 U/l (median: 120 U/l).
The ränge of bone alkaline phosphatase mass concentration in these patients was 16-206 pg/l (median: 27 g/l). Out of 20 sera, 18 (90%) showed a bone alkaline phosphatäse mass concentration aböve the upper reference limit (21. 
Discussion
The immunoradiometric determination of bone alkaline phosphatase is characterized by a linear relationship between the mass concentration of bone alkaline phosphatase and the measuring signal up to 120 §/1.
A drawback of the immunoradiometric assay is its high within-run and between-day imprecision for values within the normal ränge.
The upper reference limits of bone alkaline phosphatase activity concentration established by us correspond to those reported earlier (5) . There is a marked dependence of reference values on sex (5); in adults from 20 to 50 years old this may be explained by an interrelationship between bone alkaline phosphatase values and sex hormones, especially oestrogens (8).
Our results for bone alkaline phosphatase activity concentration (äs determined by precipitation with wheatgerm lectin) in patients with hepatobiliary diseases are concordant with those reported by Behr & Barnert (9), who observed that in more than half of patients with hepatitis of differing origin, äs well äs in patients with cholestasis, bone alkaline phosphatase activity concentration (äs assessed by precipitation with wheat-germ lectin) was increased (up to 725 U/l) without accompanying signs of bone affection. In coiitrast to the liver alkaline phosphatase molecules that occur in serum, those isolated from liver tissue can be precipitated with wheat-germ lectin, presumably because membrane-localized glycosyltransferases modify the enzyme molecules äs they pass into the intravasal space (9) . As a result of increased liver cell permeability in patients with hepatobiliary diseases, liver alkaline phosphatase is possibly not modified by the membrane-localized glycosyltransferases mentioned above and is therefore precipitated by wheat-germ lectin, resulting in falsely high values for bone alkaline phosphatase activity concentration. Biliary alkaline phosphatase, which is a complex of liver alkaline phosphatase with membrane fragments, is not responsible for implausibly high values of bone alkaline phosphatase activity concentration, because Triton X-100 prevents coprecipitation of this isoform (9) .
Falsely high levels of bone alkaline phosphatase mass concentration are possibly due to cross-reactivity of the antibodies employed for the immunoassay of bone alkaline phosphatase with liver alkaline phosphatase (10) , so that the diagnostic validity of the test is strongly limited in patients with an increased release of liver alkaline phosphatase into plasma.
Further investigations are required to determine the clinical value of the immunochemical determination of bone alkaline phosphatase mass concentration in serum.
